Display options
Cite
Rothschild HT, Abel MK, Patterson A, et al. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Res Treat. 2021;191(2):451-458doi: 10.1007/s10549-021-06453-8.
Rothschild, H. T., Abel, M. K., Patterson, A., Goodman, K., Shui, A., van Baelen, K., Desmedt, C., Benz, C., & Mukhtar, R. A. (2022). Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast cancer research and treatment, 191(2), 451-458. https://doi.org/10.1007/s10549-021-06453-8
Rothschild, Harriet T, et al. "Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer." Breast cancer research and treatment vol. 191,2 (2022): 451-458. doi: https://doi.org/10.1007/s10549-021-06453-8
Rothschild HT, Abel MK, Patterson A, Goodman K, Shui A, van Baelen K, Desmedt C, Benz C, Mukhtar RA. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Res Treat. 2022 Jan;191(2):451-458. doi: 10.1007/s10549-021-06453-8. Epub 2021 Nov 24. PMID: 34817747.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer Res Treat. 2022 Jan;191(2):451-458. doi: 10.1007/s10549-021-06453-8. Epub 2021 Nov 24.

Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.

Breast cancer research and treatment

Harriet T Rothschild, Mary Kathryn Abel, Anne Patterson, Kent Goodman, Amy Shui, Karen van Baelen, Christine Desmedt, Christopher Benz, Rita A Mukhtar

Affiliations

  1. School of Medicine, University of California, San Francisco, CA, 94143, USA. [email protected].
  2. School of Medicine, University of California, San Francisco, CA, 94143, USA.
  3. Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, CA, 94143, USA.
  4. Department of Surgery Biostatistics Core, University of California, San Francisco, CA, 94143, USA.
  5. Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, B-3000, Leuven, Belgium.
  6. Buck Institute for Research On Aging, Novato, CA, 94945, USA.

PMID: 34817747 DOI: 10.1007/s10549-021-06453-8

Abstract

PURPOSE: We investigated the relationship between obesity, menopausal status, and invasive lobular carcinoma (ILC), the second most common histological subtype of breast cancer. Specifically, we evaluated the association between body mass index (BMI), metabolic syndrome, the 21-gene Oncotype Recurrence Score (Oncotype RS), and pathological features in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2-negative ILC.

METHODS: The study cohort included 491 patients from a prospectively maintained institutional database consisting of patients with stage I-III, HR-positive ILC who underwent surgical treatment between 1996 and 2019.

RESULTS: Contrary to our expectations, we found that lower BMI was significantly associated with having higher Oncotype RS (18.9% versus 4.8%, p = 0.028) in post-menopausal patients, but was not related to tumor characteristics in pre-menopausal patients. Multivariate network analyses suggested a strong relationship between post-menopausal status itself and tumor characteristics, with lesser influence of BMI.

CONCLUSION: These findings provide further insight into the recently appreciated heterogeneity within ILC and support the need for further investigation into the drivers of this disease and tailored treatment strategies.

© 2021. The Author(s).

Keywords: BMI; Invasive lobular carcinoma; Menopausal status; Metabolic syndrome; Oncotype RS

References

  1. Sledge GW, Chagpar A, Perou C (2016) Collective wisdom: lobular carcinoma of the breast. Am Soc Clin Oncol. https://doi.org/10.1200/EDBK_100002 - PubMed
  2. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L (1995) Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85:11–17. https://doi.org/10.1016/0029-7844(94)00324-7 - PubMed
  3. Dossus L, Benusiglio PR (2015) Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 17:37. https://doi.org/10.1186/s13058-015-0546-7 - PubMed
  4. O’Connor IF, Shembekar MV, Shousha S (1998) Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 51:935–938. https://doi.org/10.1136/jcp.51.12.935 - PubMed
  5. Rakha EA, Ellis IO (2010) Lobular breast carcinoma and its variants. Semin Diagn Pathol 27:49–61. https://doi.org/10.1053/j.semdp.2009.12.009 - PubMed
  6. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE (2000) Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88:2561–2569. https://doi.org/10.1002/1097-0142(20000601)88:11%3c2561::AID-CNCR19%3e3.0.CO;2-X - PubMed
  7. Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ (2021) Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djab023 - PubMed
  8. Goodwin PJ, Stambolic V (2015) Impact of the obesity epidemic on cancer. Annual Review of Med 66:281–296. https://doi.org/10.1146/annurev-med-051613-012328 - PubMed
  9. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med 375:794–798. https://doi.org/10.1056/NEJMsr1606602 - PubMed
  10. Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15:484–498. https://doi.org/10.1038/nrc3967 - PubMed
  11. The GBD 2015 Obesity Collaborators (2016) Health effects of overweight and obesity in 195 countries over 25 Years. N Engl J Med 377:13–27. https://doi.org/10.1056/NEJMoa1614362 - PubMed
  12. Jiralerspong S, Goodwin PJ (2016) Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J of Clin Oncol 34:4203–4216. https://doi.org/10.1200/JCO.2016.68.4480 - PubMed
  13. Bernstein L, Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48–65. https://doi.org/10.1093/oxfordjournals.epirev.a036116 - PubMed
  14. Quail DF, Dannenberg AJ (2019) The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol 15:139–154. https://doi.org/10.1038/s41574-018-0126-x - PubMed
  15. Vona-Davis L, Howard-McNatt M, Rose DP (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 8:395–408. https://doi.org/10.1111/j.1467-789X.2007.00396.x - PubMed
  16. Torres-de la Roche LA, Steljes I, Janni W, Friedl TWP, De Wilde RL (2020) The association between obesity and premenopausal breast cancer according to intrinsic subtypes—a systematic review. Geburtshilfe Frauenheilkd 80:601–610. https://doi.org/10.1055/a-1170-5004 - PubMed
  17. Robinson PA, Treece T, Osipo C, Qamar R, Zon R, Levine EG, Budway R, Mavromatis BH, Untch S, Bernards R, Audeh MW, Soliman HH (2018) Effect of metabolic syndrome on risk of recurrence and immune pathways in invasive lobular carcinoma disparately compared to ductal. J of Clin Oncol 36:e24229. https://doi.org/10.1200/JCO.2018.36.15_suppl.e24229 - PubMed
  18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235. https://doi.org/10.1007/s10549-006-9242-8 - PubMed
  19. Pomponio M, Burkbauer L, Goldbach M, Keele L, Allison KC, Li YR, Nazarian SM, Tchou J (2020) Is there an association between body mass index and 21-gene recurrence score? Surgical Oncol 34:74–79. https://doi.org/10.1016/j.suronc.2020.01.007 - PubMed
  20. Sahin S, Erdem GU, Karatas F, Aytekin A, Sever AR, Ozisik Y, Altundag K (2017) The association between body mass index and immunohistochemical subtypes in breast cancer. Breast 32:227–236. https://doi.org/10.1016/j.breast.2016.09.019 - PubMed
  21. Suba Z (2013) Circulatory estrogen level protects against breast cancer in obese women. Recent Pat Anti-Cancer Drug Discov 8:154–167. https://doi.org/10.2174/1574892811308020004 - PubMed
  22. Tubtimhin S, Promthet S, Suwanrungruang K, Supaattagorn P (2018) Molecular subtypes and prognostic factors among premenopausal and postmenopausal Thai women with invasive breast cancer: 15 years follow-up data. Asian Pac J Cancer Prev 19:3167–3174. https://doi.org/10.31557/APJCP.2018.19.11.3167 - PubMed
  23. Picardo S, Sui J, Greally M, Woulfe B, Prior L, Corrigan L, O’Leary C, Mullally W, Walshe J, McCaffrey J, O’Connor M, O’Mahony D, Coate L, Gupta R, O’Reilly S (2017) Oncotype DX score, menopausal status and body mass index. Ann of Oncol 28:59. https://doi.org/10.1093/annonc/mdx362.043 - PubMed
  24. Christgen M, Gluz O, Harbeck N, Kates RE, Raap M, Christgen H, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Krabisch P, Just M, Augustin D, Graeser M, Baehner F, Wuerstlein R, Nitz U, Kreipe H (2020) Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer. Cancer 126:4847–4858. https://doi.org/10.1002/cncr.33104 - PubMed
  25. Cha YJ, Kim HM, Koo JS (2017) Expression of lipid metabolism-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Int J Mol Sci 18:232. https://doi.org/10.3390/ijms18010232 - PubMed
  26. Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B, Oesterreich S (2018) Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 20:106. https://doi.org/10.1186/s13058-018-1041-8 - PubMed
  27. Li B, Hao J, Yan X, Kong M, Sauter ER (2019) A-FABP and oestrogens are independently involved in the development of breast cancer. Adipocyte 8:379–385. https://doi.org/10.1080/21623945.2019.1690827 - PubMed
  28. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR (2000) Aberrant methylation of the estrogen receptor and e-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 60:4346–4348 - PubMed
  29. Corso G, Figueiredo J, De Angelis SP, Corso F, Giardi A, Pereira J, Seruca R, Bonanni B, Carneiro P, Pravettoni G, Rocco EG, Veronesi P, Montagna G, Sacchini V, Gandini S (2020) E-cadherin deregulation in breast cancer. J Cell Mol Med 24:5930–5936. https://doi.org/10.1111/jcmm.15140 - PubMed
  30. Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, Giordano C, Bartella V, Casaburi I, Ando S (2007) Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor grown and progression. Can Res 67:3412–3421. https://doi.org/10.1158/0008-5472.CAN-06-2890 - PubMed

Publication Types